{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:50:02Z","timestamp":1792601402406,"version":"4.5.0"},"reference-count":9,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Denosumab is a RANK-L inhibitor used off-label as a treatment for a variety of pediatric bone disorders, including aneurysmal bone cysts (ABC). Rebound hypercalcemia is a known side effect after denosumab therapy and is more commonly reported in pediatric patients. Although there are no established treatment guidelines, denosumab-induced rebound hypercalcemia is usually managed with a combination of intravenous fluids, diuretics, corticosteroids, denosumab, and\/or bisphosphonates. We present the case of a 10-year-old female patient with history of a right sacral ABC treated with denosumab who presented with recurrent episodes of rebound hypercalcemia beginning 3 months after denosumab cessation. After the third hospitalization for hypercalcemia, which was treated with zoledronic acid, normocalcemia was achieved. This case demonstrates an increasingly recognized side effect of denosumab therapy that occurs mainly in skeletally immature patients and presents a possible approach to initial therapy of rebound hypercalcemia with a long-acting bisphosphonate.<\/jats:p>","DOI":"10.1210\/jcemcr\/luad133","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T13:38:56Z","timestamp":1698500336000},"source":"Crossref","is-referenced-by-count":12,"title":["Denosumab-Induced Rebound Hypercalcemia Treated With Bisphosphonates in a Pediatric Patient"],"prefix":"10.1210","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3366-5677","authenticated-orcid":false,"given":"Anne","family":"Gandolfi","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Rush University Medical Center, Rush Pediatric Residency Program , Chicago, IL 60612 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Shaaban","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, Rush University Medical Center , Chicago, IL 60612 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,10,28]]},"reference":[{"key":"2023102813384846000_luad133-B1","doi-asserted-by":"crossref","first-page":"101148","DOI":"10.1016\/j.bonr.2021.101148","article-title":"Hypercalcemia following discontinuation of denosumab therapy: a systematic review","volume":"15","author":"Horiuchi","year":"2021","journal-title":"Bone Rep"},{"issue":"4","key":"2023102813384846000_luad133-B2","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11914-017-0380-1","article-title":"Denosumab: an emerging therapy in pediatric bone disorders","volume":"15","author":"Boyce","year":"2017","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"2023102813384846000_luad133-B3","doi-asserted-by":"crossref","first-page":"105260","DOI":"10.1016\/j.jbspin.2021.105260","article-title":"Denosumab in the management of Aneurysmal bone cyst","volume":"89","author":"Maximen","year":"2022","journal-title":"Joint Bone Spine"},{"issue":"5","key":"2023102813384846000_luad133-B4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/0300891618784808","article-title":"Denosumab in patients with aneurysmal bone cysts: a case series with preliminary results","volume":"104","author":"Palmerini","year":"2018","journal-title":"Tumori J"},{"issue":"1","key":"2023102813384846000_luad133-B5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40618-021-01630-4","article-title":"Mechanisms of acute hypercalcemia in pediatric patients following the interruption of Denosumab","volume":"45","author":"Deodati","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2023102813384846000_luad133-B6","first-page":"e3989","article-title":"Denosumab therapy in the management of aneurysmal bone cysts: a comprehensive literature review","volume":"11","author":"Alhumaid","year":"2019","journal-title":"Cureus"},{"issue":"6","key":"2023102813384846000_luad133-B7","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.otsr.2019.04.028","article-title":"Denosumab for treating aneurysmal bone cysts in children","volume":"105","author":"Raux","year":"2019","journal-title":"Orthop Traumatol Surg Res"},{"issue":"5","key":"2023102813384846000_luad133-B8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00223-023-01065-4","article-title":"Mitigating the denosumab-induced rebound phenomenon with alternating short- and long-acting anti-resorptive therapy in a young boy with severe OI type VI","volume":"112","author":"Seale","year":"2023","journal-title":"Calcif Tissue Int"},{"key":"2023102813384846000_luad133-B9","first-page":"8854441","article-title":"The efficacy of denosumab in the management of a tibial paediatric aneurysmal bone cyst compromised by rebound hypercalcaemia","volume":"2020","author":"Harcus","year":"2020","journal-title":"Case Rep Pediatr"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/1\/5\/luad133\/52660594\/luad133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/1\/5\/luad133\/52660594\/luad133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T13:39:01Z","timestamp":1698500341000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luad133\/7332044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luad133","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,9,1]]},"article-number":"luad133"}}